(Total Views: 53)
Posted On: 07/09/2025 4:39:48 PM
Post# of 117
NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Multiple 2025–2026 Catalysts Across Rare Disease Pipeline
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a shareholder update outlining key clinical and strategic milestones. President and CEO Dr. Christopher J. Schaber highlighted upcoming data readouts for lead candidates, including Phase 3 FLASH 2 results for HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma expected in 2H 2026, and multiple updates in 3Q and 4Q 2025 across psoriasis (SGX302) and Behçet’s Disease (SGX945). An investigator-initiated study also showed a 75% success rate at 18 weeks. The company projects HyBryte(TM) peak U.S. annual sales of over $90 million and global opportunities exceeding $2 billion across its pipeline. With approximately $7 million in cash and active exploration of partnerships and M&A, Soligenix aims to extend its cash runway into 1Q 2026 while preparing for global regulatory filings and potential commercialization.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a shareholder update outlining key clinical and strategic milestones. President and CEO Dr. Christopher J. Schaber highlighted upcoming data readouts for lead candidates, including Phase 3 FLASH 2 results for HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma expected in 2H 2026, and multiple updates in 3Q and 4Q 2025 across psoriasis (SGX302) and Behçet’s Disease (SGX945). An investigator-initiated study also showed a 75% success rate at 18 weeks. The company projects HyBryte(TM) peak U.S. annual sales of over $90 million and global opportunities exceeding $2 billion across its pipeline. With approximately $7 million in cash and active exploration of partnerships and M&A, Soligenix aims to extend its cash runway into 1Q 2026 while preparing for global regulatory filings and potential commercialization.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
